C ytomegalovirus (CMV) has a high seroprevalence in adults depending on geographical and social factors. Population screening showed that 40% to 100% are infected during childhood (1); a positive CMV seroprevalence has been shown in 70% of the adolescent population (2) . Although a febrile illness is possible, primary infection is frequently asymptomatic in immunocompetent hosts (3) . After this primary infection, the virus establishes latency in many tissues. As all herpes viruses do, CMV can reactivate during episodes of diminished immunity and frailty.
The morbidity and mortality of primary infection and reactivation of CMV in immunocompromised patients has been described for several decades. However, the first reports on the reactivation of CMV in "immunocompetent" critically ill burn patients date only to the late '80's (4) . These reports used an increase in CMV antibodies as evidence for reactivation, a method that is poorly reliable (5) . In the '90's, the investigations extended to surgical and medical intensive care units (ICUs). Several surveys reported an association between CMV reactivation during ICU stay and morbidity as assessed by an increased length of ICU and hospital stay (5) (6) (7) (8) (9) (10) (11) (12) (13) , longer need for mechanical ventilation (5, 8, 9, (11) (12) (13) (14) and renal replacement therapy (6, 9) , and increased risk of developing nosocomial bacterial infections (6, 8, 9, 12 ). Yet there are only two retrospective studies (9, 11) , one meta-analysis (15) and one prospective study based on viral cultures (16) , that show a significant association between CMV reactivation and increased mortality in the overall nonimmunocompromised ICU population. The study by Jaber et al (9) was performed in patients with fever lasting Ͼ72 hrs. Although the mortality was higher in the CMV-seropositive group, reactivation of CMV was not identified as an independent risk factor for mortality after correction for other patients' characteristics using multivariable logistic regression analysis. Ziemann et al (11) demonstrated an association between CMV reactivation and increased mortality in patients with prolonged ICU stay, without taking additional clinical selection criteria into account. The recent meta-analysis by Kalil and Florescu (15) showed that active CMV replication is associated with an almost doubled mortality rate. Cook et al (16) showed a higher ICU mortality in surgical ICU (SICU) patients with positive cytomegalovirus cultures.
CMV replication is the result of reactivation of a latently infecting virus rather than a new infection during ICU admission, and thus almost only occurs in CMV-seropositive patients (8, 11, 14, 17) . Based on previous results, the question arises whether prophylactic therapy to prevent CMV reactivation would improve outcome of CMV-seropositive critically ill patients. Voices to perform an interventional study in CMV-seropositive patients emerge (6, 10, 18, 19) . In the light of these suggestions, we investigated whether CMV seropositivity is independently associated with adverse outcome in nonimmunocompromised critically ill patients.
MATERIALS AND METHODS

Study Population
We analyzed serum samples that were collected during the intensive insulin therapy studies performed in a large, 1900-bed referral center by Van den Berghe et al (20, 21) . The original studies focus on the role of normalization of blood glucose levels with intensive insulin therapy in surgical and medical critically ill patients (20, 21) . The first study was performed in a 56-bed SICU; inclusion of patients was done from February 2, 2000 until January 18, 2001 . Only mechanically ventilated patients were eligible for enrollment. The second study was performed in a 17-bed medical ICU (MICU); inclusion was carried out between March 2002 and May 2005. Patients who could take oral nutrition and patients who had received a do-not-resuscitate order before or at admission as well as surgical patients were excluded. Serum samples of study patients were stored at Ϫ80°C for future additional analysis.
Our current study focuses on nonimmunocompromised critically ill patients from whom serum obtained on day 1 or 2 after ICU admission was available. We excluded solid organ and stem cell transplanted recipients, patients with hematologic malignancy and myelodysplasia, and patients receiving chemotherapy or other immunosuppressive agents (except corticosteroids). Because CMV reactivation does not occur immediately after ICU admission, only patients with an ICU length of stay of at least 3 days were eligible for inclusion. The study has been approved by the Institutional Review Board and an informed consent provided by next of kin was obtained for all patients.
Study Design
We analyzed CMV serology on serum samples prospectively collected within the first 2 days of ICU admission. The following risk factors for adverse outcome were collected: age, gender, body mass index (BMI), medical history of malignancy and diabetes mellitus, type of ICU (MICU vs. SICU), randomization arm in the glycemia control study, admission diagnostic category, acute physiology and chronic health evaluation (APACHE) II score, mechanical ventilation, presence of sepsis at admission, need for norepinephrine as vasopressor agent, treatment with corticosteroids, number of transfused packed cells per week of ICU stay, and serostatus to CMV using immunoglobulin G detection. Outcome parameters were ICU and in-hospital mortality, time to alive ICU and hospital discharge, time to alive weaning from mechanical ventilation, and need for renal replacement therapy. The admission diagnostic categories were divided into cardiovascular, abdominal, or thoracic (including esophageal and pulmonary) pathology, and diseases that did not fit any of those were classified in the fourth category "others." The patients admitted after trauma or cardiovascular surgery were excluded for the diagnosis of sepsis at admission, since the criteria according to Bone et al (22) do not apply to these patients. All administrated packed cells were leukoreduced using prestorage leukoreduction.
Due to the timing of the analyses performed with clinically available methodology, the samples from patients in the MICU study were analyzed with the Axsym system (Abbott Laboratories Diagnostic Division, Abbott Park, IL); those from the SICU patients with the Architect CMV assay (Abbott Laboratories Diagnostic Division). We used the cutoff values that were suggested by the manufacturer to define seropositivity. A prospective survey in our center before transition of clinically used CMV serostatus assay has shown a correlation of Ͼ94% between the Axsym and Architect immunoglobulin G test (23) .
The primary end point was ICU mortality from any cause. Secondary end points were in-hospital mortality, time to alive discharge from ICU and hospital, time to alive weaning from mechanical ventilation, and the need for renal replacement therapy.
Statistical Analysis
The risk profile of the CMV seronegatives and CMV seropositives were compared using the Student's t test, Mann-Whitney U test, and the chi-square test. A two-sided test of p Ͻ .05 was judged to be significant. The data are presented as mean Ϯ SD for normally distributed parameters. The BMI was assessed as a categorical variable by defining four groups. Secondly, multivariable logistic regression analysis was performed for the nominal outcome parameters ICU and hospital mortality. No further model reduction was done. Proportional hazards Cox regression analysis was used for the time-to-event analyses, such as time to alive discharge from ICU and hospital, time to alive weaning from mechanical ventilation, and time to need for renal replacement therapy. For this Cox proportional hazard time-to-event analyses, the nonsurvivors were censored beyond the longest duration of the survivors. This was done by giving the deceased patients a censored observation time larger than the largest observed event time, this method has been described by Andersen et al (24) . All risk factors were entered into the proportional hazard model without prior selection. Statistical analysis was done with Statview 5.0. (SAS Institute, Cary, NC).
RESULTS
Serum samples from 1,504 patients (739 MICU and 765 SICU) were examined ( Fig. 1 ).
Risk Profile of the CMV-Seronegative and CMV-Seropositive Groups
Overall, 64% of the patients tested positive for CMV immunoglobulin G antibodies. The risk profiles of the CMVseropositive and CMV-seronegative patients were not fully comparable ( Table  1 ). The CMV-seropositive patients were significantly older and comprised fewer men than the seronegative patients. The proportion of MICU patients tended to be higher in the CMV-seronegative group. There was also a difference in the admission diagnostic category, with proportionally fewer cardiovascular and thoracic patients in the CMV-seronegative group. A larger fraction of the CMV-seropositive patients had diabetes mellitus. The administration of packed cells, steroids, and norepinephrine, as well as the APACHE II score, the BMI, and presence of a diagnosis of sepsis at admission was comparable in both serostatus groups. Overall, 89% of all patients received mechanical ventilation. The need for mechanical ventilation was higher in the CMV-seropositive patients than in the CMV-seronegative patients.
Outcome
Primary End Point: ICU Mortality. The overall ICU mortality was higher in the MICU patients (27.8%) than in the SICU patients (10.5%). In the univariable analysis, ICU mortality in CMV-seropositive patients (19 Multivariable logistic regression analysis revealed that older age (p Ͻ .0001), a positive history of malignancy (p Ͻ .001), higher APACHE II (p Ͻ .0001), more red blood cell transfused per week of ICU stay (p Ͻ .0001), administration of steroids (p Ͻ .0001) and norepinephrine (p Ͻ .0001), and need for mechanical ventilation (p Ͻ .0001) were independently associated with a higher risk of ICU mortality. Obesity with a BMI of 31 or more was associated with a lower ICU mortality (p ϭ .01). Patients allocated to the intensive glycemia control group tended to have a lower mortality (p ϭ .06). The CMV serostatus, however, was not associated with ICU mortality (p ϭ .58, OR 1.10, 95% CI 0.78 -1.56) ( Table 2) . Multivariable logistic regression analysis revealed that older age (p Ͻ .0001), history of malignancy (p Ͻ .0001), higher APACHE II scores (p Ͻ .0001), more packed cells transfused per week of ICU stay (p Ͻ .0001), and the administration of steroids (p Ͻ .0001) and norepinephrine (p Ͻ .0001) were independently associated with a higher risk of hospital mortality. Higher BMI (31 kg/m 2 or more) and randomization to the strict glycemia control group were independently associated with a lower risk of hospital mortality (p ϭ .02 and p Ͻ .01, respectively). The CMV serostatus, however, was not independently associated with hospital mortality (p ϭ .19, OR 1.22, 95% CI 0.91-1.65) ( Table 2) .
Secondary End Points
The hospital length of stay was comparable for CMV-seronegative (median stay 21 days) and CMV-seropositive patients (median stay 20 days) (p ϭ .27, HR 0.848, 95% CI 0.688 -1.044). A Cox proportional hazard regression analysis, censoring nonsurvivors beyond the longest stay of survivors, revealed no independent association between CMV serology and time to alive discharge from the hospital (p ϭ .58, HR 0.96, 95% CI 0.85-1.10). A higher chance for early alive discharge was observed for admission to Table 2) . The proportion of patients needing renal replacement therapy was the same in both groups using univariable analysis (16.8% in the CMV-seronegative group vs. 15.6% in the CMV-seropositive group, OR 0.915, 95% CI 0.688 -1.218). We found no independent association between CMV serostatus and the need for renal replacement therapy as assessed by Cox proportional hazard regression analysis (p ϭ .43, HR 1.12, 95% CI 0.85-1.46). Several factors were independently associated with a higher risk for renal replacement therapy. Those factors were the administration of norepinephrine (p Ͻ .0001) and steroids (p Ͻ .0001), amount of transfused packed cells (p Ͻ .0001), and higher APACHE II scores (p Ͻ .0001) ( Table 2) .
Subgroup Analyses for the Risk of Mortality According to CMV Serostatus
Subgroup Analysis for Different Durations of ICU Stay. We performed a subgroup analysis for patients who stayed in the ICU for at least 7 or 14 days. Using multivariable logistic regression analysis, we found no independent risk associated with CMV seropositivity among the 679 patients staying at least 7 days (ICU mortality OR 1. 25 By adding the interaction between CMV serostatus and the ICU LOS, none of the interaction p values were significant, and the risk ratios as well as the ORs remained the same.
Subgroup Analysis for Patients with Sepsis at Admission. Among the 608 patients with sepsis at admission, we could not find an independent association between CMV seropositivity and ICU mor-
This result was not altered by only considering those patients with sepsis at admission and with an ICU stay of 7 days or more (348 patients), nor those with an ICU stay of 14 days or more (205 patients) (data not shown).
By adding the interaction between CMV serostatus and sepsis at admission, none of the interaction p values were significant, and the risk ratios as well as the ORs remained the same.
Subgroup Analysis for Type of ICU (MICU vs. SICU). When considering MICU (n ϭ 736) and SICU (n ϭ 755) patients separately, CMV seropositivity was not independently associated with ICU or hospital mortality (data not shown).
By adding the interaction between CMV serostatus and type of ICU, none of the interaction p values were significant and the risk ratios as well as the ORs remained the same.
Subgroup Analysis in Patients with Higher APACHE II Scores. When only including the 1,043 patients with an APACHE II score of 10 or more, there was no difference in the ICU or in-hospital mortality in the CMV-seropositive patients as compared to the CMV-seronegative patients (data not shown). The same results were found in the 720 patients with an APACHE II score of 15 or more (data not shown).
By adding the interaction between CMV serostatus and the APACHE II scores, none of the interaction p values were significant, and the risk ratios as well as the ORs remained the same.
DISCUSSION
This study compares the clinical outcome of CMV-seropositive with CMVseronegative critically ill, nonimmunocompromised patients. We could not demonstrate an independent association between the CMV serostatus and ICU mortality, nor between the CMV serostatus and all other secondary end points investigated, whether assessed in the total group of ICU patients or in all subpopulations studied.
Other investigators observed an association between CMV reactivation and increased mortality and morbidity, and inevitably the question arises whether prophylactic therapy of all CMV seropositive patients, to prevent reactivation, would improve outcome. With the present data, this hypothesis seems unlikely.
Reactivation of CMV in ICU patients does not seem to occur immediately, with delays of a median 4 days after onset of critical illness reported (25) . Limaye et al (10) showed that half of the patients reactivated within the first 12 days after ICU admission. Heininger et al (7) revealed an average delay of 10.8 days between ICU admission and CMV reactivation, and in the retrospective study by Jaber et al (9) , the mean time to reactivation based on antigen detection was 20 days. Kalil and Florescu (15) found a reactivation rate of 1% in studies that screened only for the first 5 days post admission, without taking CMV serology into consideration. In the studies that screened for a longer period of time, the reactivation rate was 21%. In a French study, none of the 23 CMV-positive patients showed reactivation using viral culture and polymerase chain reaction (26) . The latency to reactivation can be explained by the long life cycle of the virus (3). Based on these results, we excluded patients who stayed in the ICU for less than 3 days. Since we could not find any difference in the outcome of CMVseropositive and CMV-seronegative patients, we also performed subgroup analyses for ICU and in-hospital mortality in patients with a prolonged ICU length of stay, such as more than 7 or Ͼ14 days. The results remained the same in those two subgroups, again showing no difference in ICU or in-hospital mortality.
Heininger et al (7) defined sepsis as a risk factor for reactivation. This association was not found by Jaber et al (9) . A possible link between sepsis and CMV reactivation is the higher reactivation rate when sympathetic hyperactivity occurs (27) . In our subgroup analysis of patients who suffered from sepsis at admission, we did not find any difference in the ICU mortality or in the in-hospital mortality of CMV-seropositive and CMV-seronegative patients. Kutza et al (25) found that CMV reactivates at a median of 4 days after the onset of sepsis. Nevertheless, the ICU and hospital mortality did not differ between CMV-seropositive and CMVnegative patients with sepsis at admission and an ICU length of stay of Ͼ1 or Ͼ2 wks.
We recognize that our study has limitations. First, since only one-third of all the seropositive patients suffered from reactivation, the effect of CMV reactivation is weakened by the majority of seroposi-tive patients that were seropositive but did not have CMV reactivation. Furthermore, we cannot exclude that some of the CMV-seronegative patients had a primary CMV infection. However, the main purpose of our study was to investigate whether prophylaxis by means of antiviral drugs in all CMV seropositive patients, without additional arguments for CMV reactivation, would be worthwhile to pursue in a randomized controlled setting. Our study results do not provide a rationale for such a trial, and indicate that any potential benefit is likely to be small. Second, this is a single-center study. However, the study was performed in both the adult medical and adult surgical ICUs, each run by independent teams of physicians and nurses, and comprising the full spectrum of nonimmunocompromised adult ICU patients. Furthermore, the results were similar whether we looked in the medical or the surgical patient population separately, or both combined.
Third, we analyzed patients with an ICU length of stay of 3 days or more. Previous studies revealed that CMV reactivated after 5 to 10 days of ICU admission. For this reason we also performed subanalyses of patients with an ICU length of stay of at least 7 and 14 days, which again did not show a higher mortality in the CMV-seropositive group.
Finally, the mortality rate was lower in our population compared to other studies concerning this topic. Consequently, our current study was statistically underpowered to significantly detect a small 2.1% difference in ICU mortality and the 4% difference in hospital mortality with serostatus. However, our study investigated the largest population on this topic so far, and did have 75% one-tailed power to detect a larger difference in ICU mortality of 5%, and thus should be considered directive for future studies.
Our findings are important to define the next step in the evaluation of the effect of CMV reactivation. During recent years, several authors suggested the need for an interventional, double-blind, randomized placebo-controlled trial (5, 6, 10, 18, 19) , and the first animal studies to define the optimal dose have been performed (28, 29) . Our results provide an argument against such a prophylactic trial in otherwise unselected CMVseropositive critically ill patients. Since we could not demonstrate a worse outcome in this group, a clear benefit of antiviral treatment for this group as a whole is unlikely. Furthermore, all drugs that are clinically active against CMV carry significant risks of drug toxicity, can induce drug resistance, and are costly. We agree with Heininger and Hamprecht (30) and with Kalil (31) on the fact that subgroups of severely ill patients who should be enrolled in studies on antiviral treatment should be identified before such a trial can be designed. Several potential risk factors have been investigated, such as sepsis and septic shock (5, 7, 25) , low-dose steroids (8, 9) , prolonged hospital stay (5, (7) (8) (9) , and blood transfusions (8, 9) . A recent study showed a high reactivation rate of 71% in 21 CMV-seropositive burn patients (32) . Further investigation should focus on these risk factors to evaluate whether antiviral prophylaxis is recommended in CMV-seropositive critically ill patients with additional risk factors.
CONCLUSION
Although CMV reactivation seems to occur frequently in CMV-seropositive, nonimmunocompromised critically ill patients, the impact of this reactivation on the outcome remains unclear. This study, performed in a large mixed nonimmunocompromised ICU population, showed no evidence for a worse outcome in CMV-seropositive vs. CMV-seronegative critically ill patients. Based on these results, further investigation to define risk factors for CMV reactivation is necessary before we could eventually move to interventional studies in nonimmunocompromised critically ill patients, which cannot be based on CMV serology only.
